Does Dr. KAREN ACEVEDO-MOGHARBEL have financial conflicts of interest?

Dr. KAREN ACEVEDO-MOGHARBEL (D.O) has received a total of $33,753 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $33,753 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. KAREN ACEVEDO-MOGHARBEL?

According to CMS Open Payments data, Dr. KAREN ACEVEDO-MOGHARBEL received funding from NOVO NORDISK ($29,725), ASTRAZENECA PHARMACEUTICALS ($1,118), and ABBVIE ($615).

Does Dr. KAREN ACEVEDO-MOGHARBEL receive research grants or speaking fees?

Dr. KAREN ACEVEDO-MOGHARBEL has received $33,753 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. KAREN ACEVEDO-MOGHARBEL

D.OReal-Time Hydrated

Specialty: Family Medicine

Practice Location: MESA, AZ 85212

NPI Number: 1245222074

LIFETIME INDUSTRY VALUE

$33,753

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ACEVEDO-MOGHARBEL is a verified Family Medicine practitioner based in MESA, AZ.

Between 2021 and 2024, Dr. ACEVEDO-MOGHARBEL had an overall industry promotional and research financial footprint of $33,753 as recorded in the federal CMS Open Payments database.

$33,753 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ACEVEDO-MOGHARBEL's primary funding source is NOVO NORDISK, which accounts for $29,725 (representing 88.1% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

NOVO NORDISK

Rank 1

$29,725

88.1%

ASTRAZENECA PHARMACEUTICALS

Rank 2

$1,118

3.3%

ABBVIE

Rank 3

$615

1.8%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.